Pharmacia Camptosar Improves Survival In SCLC, Has Mixed Results In NSCLC
Executive Summary
Pharmacia's Camptosar (irinotecan, CPT-11) plus cisplatin demonstrated a survival benefit in a Phase III trial in small cell lung cancer presented May 22 at the American Society of Clinical Oncology annual meeting in New Orleans.